Mounjaro for weight loss and diabetes: how the drug works

Mounjaro is a tirzepatide injection approved in the US for adults with type 2 diabetes. Here is how it works, what is known about weight loss, and what US patients should discuss with their doctors.

Mounjaro is the brand name for tirzepatide, a once-weekly injectable prescription medicine approved by the US Food and Drug Administration (FDA) in May 2022 to improve blood sugar control in adults with type 2 diabetes when used with diet and exercise FDA, 05/13/2022. It is manufactured by Eli Lilly.

As of: 05/21/2026 | Reading time: approx. 7 minutes

By the AD HOC NEWS editorial team - specialized in product-focused market coverage.

At a Glance

• Product: Mounjaro (tirzepatide)
• Category: Injectable GLP-1/GIP receptor agonist
• Brand/Manufacturer: Eli Lilly
• Primary Use Cases: Blood sugar control in adults with type 2 diabetes
• Availability: Prescription only in the United States via pharmacies
• Core Markets: United States and other major global diabetes markets

What Mounjaro Is and How It Works

Mounjaro contains tirzepatide, a synthetic peptide that activates receptors for two hormones involved in blood sugar and appetite regulation, called GIP and GLP-1. The FDA describes it as the first approved GIP and GLP-1 receptor agonist for type 2 diabetes in adults FDA, 05/13/2022.

Like other GLP-1 based drugs, tirzepatide helps the pancreas release insulin when blood sugar is high and reduces the amount of sugar made by the liver. It also slows how fast food leaves the stomach. Eli Lilly explains that tirzepatide targets GIP and GLP-1 receptors to improve glycemic control in adults with type 2 diabetes Eli Lilly, 05/13/2022.

Because these hormones act on the brain and digestive system, many users notice reduced appetite and smaller meal sizes. This effect has raised strong interest in Mounjaro as a weight management tool, although in the United States its approved indication is type 2 diabetes treatment, not cosmetic weight loss FDA, 05/13/2022.

Why Mounjaro Matters for US Consumers and Industry

Type 2 diabetes affects millions of adults in the United States and is a major driver of heart disease, kidney failure, and vision loss. The Centers for Disease Control and Prevention reports that more than 37 million Americans have diabetes, the vast majority type 2 CDC, 11/01/2022. This makes effective treatments like Mounjaro highly relevant.

In pivotal phase 3 studies, tirzepatide given once weekly led to larger reductions in HbA1c, a key marker of long term blood sugar control, than the GLP-1 agonist semaglutide among adults with type 2 diabetes. Results from the SURPASS program were published in the New England Journal of Medicine in 2021 NEJM, 07/29/2021.

Because many adults with type 2 diabetes in the US also live with overweight or obesity, a medication that tackles blood sugar and body weight in one weekly injection has clear appeal. US media and health systems have highlighted how GLP-1 based drugs are changing diabetes and obesity care New York Times, 11/22/2023.

Mounjaro in the US and Global Market

Since its initial launch, Mounjaro has been rolled out across US pharmacies as a prescription drug, typically dispensed through retail chains, hospital systems, and mail order pharmacies. Eli Lilly markets the product internationally in other regions where regulators have granted authorization Eli Lilly, 05/13/2022.

Global interest in drugs that affect GLP-1 pathways has grown rapidly, with multiple manufacturers developing or marketing similar agents for diabetes and obesity. Trade and business press in the United States have noted that GLP-1 based medicines are reshaping parts of the pharmaceutical and healthcare landscape Wall Street Journal, 08/16/2023.

Insurance coverage and out-of-pocket costs for Mounjaro can vary widely for US patients, depending on health plans and employer benefits. Many commercial insurers and some public programs cover GLP-1 based therapies for type 2 diabetes when clinical criteria are met, but coverage for obesity alone is more limited KFF, 01/24/2024.

How Mounjaro Is Taken in Everyday Use

Mounjaro is supplied as a prefilled, single use injection pen designed for once weekly subcutaneous use. Patients are typically trained by their healthcare provider on how to inject into the abdomen, thigh, or upper arm. The prescribing information describes step by step instructions for proper use and disposal of the pens Eli Lilly, 2024.

The drug is usually started at a low weekly dose and then increased gradually over weeks, if tolerated, to reduce gastrointestinal side effects such as nausea. This titration schedule is laid out in the official US prescribing information for tirzepatide, which physicians use to individualize therapy for adults with type 2 diabetes Eli Lilly, 2024.

Importantly, Mounjaro is intended to be used together with a balanced diet and regular physical activity, not as a stand alone solution. Healthcare providers often discuss lifestyle changes and may combine tirzepatide with other diabetes medicines when appropriate.

Weight Loss Effects Observed in Studies

In addition to lowering blood sugar, tirzepatide has shown meaningful weight loss in clinical trials. For adults with type 2 diabetes, phase 3 trials reported average reductions in body weight over treatment periods of several months, with higher doses generally producing larger changes. These findings were reported in the SURPASS program analyses NEJM, 07/29/2021.

Researchers have also studied tirzepatide in adults with obesity without diabetes. One large trial found substantial weight reduction over a treatment period of more than a year among participants receiving weekly tirzepatide compared with placebo, alongside dietary and physical activity guidance NEJM, 07/21/2022.

Because of these data, many US patients and clinicians are interested in tirzepatide not only for glycemic control but also as part of comprehensive weight management under medical supervision. However, final decisions about use, dose, and duration remain with licensed healthcare professionals familiar with each patient.

Safety Profile and Common Side Effects

Like all prescription medicines, Mounjaro carries potential risks and side effects. The most commonly reported adverse reactions in clinical trials include nausea, diarrhea, decreased appetite, vomiting, constipation, dyspepsia, and abdominal pain. These are described in the US prescribing information for tirzepatide Eli Lilly, 2024.

The FDA highlights that tirzepatide has a boxed warning related to thyroid C cell tumors observed in rodent studies and notes that it is unknown whether Mounjaro causes thyroid C cell tumors, including medullary thyroid carcinoma, in humans. The drug is not recommended for people with a personal or family history of medullary thyroid carcinoma or for patients with Multiple Endocrine Neoplasia syndrome type 2 FDA, 05/13/2022.

Healthcare providers may monitor patients for symptoms such as neck swelling, hoarseness, or shortness of breath and will discuss the potential risks, benefits, and alternatives before prescribing. Patients are advised to read the Medication Guide and to report side effects promptly.

How Mounjaro Fits Among Other Diabetes and Weight Drugs

In the US market, Mounjaro is one of several once weekly injectable medications used to improve blood sugar in adults with type 2 diabetes, along with drugs like semaglutide and dulaglutide. These medicines are often used when oral agents such as metformin are not enough to reach glycemic targets, as defined by clinical guidelines American Diabetes Association, 01/01/2022.

Some of these injections also have FDA approved indications for chronic weight management under specific brand names, in combination with diet and exercise. US regulators evaluate each product separately, considering efficacy, safety profile, and long term outcomes data before granting approvals for diabetes or obesity indications FDA, 10/19/2023.

For US consumers, the growing number of options can be confusing. It is important not to switch or combine therapies without guidance from a healthcare professional, because dosing, interactions, and safety considerations differ between products, even when they act on related hormone pathways.

Everyday Considerations for US Patients Using Mounjaro

Patients in the United States who use Mounjaro typically coordinate care with an endocrinologist, primary care physician, or obesity medicine specialist. These clinicians review medical history, other medications, kidney and liver function, and potential pregnancy plans before starting therapy.

Pharmacists play a practical role in explaining pen storage, timing of weekly injections, and what to do if a dose is missed. The US prescribing information provides detailed instructions on handling missed doses and on when to contact a healthcare professional for advice Eli Lilly, 2024.

Because Mounjaro is a prescription drug with specific safety warnings, it should not be obtained from informal channels or used without medical supervision. US regulators and medical societies caution against buying injectable prescription medicines from unverified sources due to risks of counterfeit or improperly stored products FDA, 02/01/2024.

Key Features and Use Cases of Mounjaro

• Once weekly injection designed to improve blood sugar in adults with type 2 diabetes who also follow diet and exercise plans.
• May help reduce body weight as observed in clinical studies, under medical supervision.
• Used in US outpatient settings, including primary care and endocrinology practices.
• Requires a prescription and regular follow up visits to monitor response and safety.

Frequently Asked Questions About Mounjaro

Is Mounjaro approved in the US for weight loss alone?
In the United States, Mounjaro is approved by the FDA to improve blood sugar in adults with type 2 diabetes alongside diet and exercise. Use for weight management beyond this indication must be guided by a licensed clinician FDA, 05/13/2022.

How long does it take to notice effects from Mounjaro?
Some patients notice changes in appetite or blood sugar within weeks, but full effects on HbA1c and weight typically build over several months of weekly use, as seen in clinical trials. Timelines vary and should be reviewed with a healthcare professional NEJM, 07/29/2021.

Can Mounjaro be taken with metformin or insulin?
Clinical practice often combines GLP-1 based drugs with other diabetes medications. The prescribing information describes how tirzepatide has been studied alongside metformin and, in some cases, insulin, but decisions on combinations are individualized by physicians Eli Lilly, 2024.

Eli Lilly and Company, based in Indianapolis, Indiana, is the pharmaceutical manufacturer behind Mounjaro. The company develops medicines in diabetes, oncology, immunology, and other therapeutic areas.

Eli Lilly shares trade on the New York Stock Exchange under the ticker LLY, and the companys registered stock carries the international securities identification number US5324571083.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.